. Author manuscript; available in PMC: 2013 Oct 1.

Published in final edited form as: Ther Drug Monit. 2012 Oct;34(5):535–544. doi: 10.1097/FTD.0b013e318261c240

Table 1.

Subject characteristics

Demographics	n (%)

Subjects	45
Children (2–12 years)	32 (71.1%)
Adolescent (12–21 years)	13 (28.8%)
Number of observations
Risperidone	168
(−)-9-hydroxyrisperidone	172
(+)-9-hydroxyrisperidone	172
Sex
Male	40 (88.9%)
Female	5 (11.1%)
Race
White	42 (93.3%)
White + Black (mixed)	3 (6.7%)
Ethnicity
Non-Hispanic	45 (100%)
Age (years)	9.6 ±3.7 (3–18.3)
Weight (kg)	43 ±20.2 (16.8–110)
	Mean ±SD (range)
Dose range (total daily dose, mg)	(0.25–6.00)
Risperidone concentration (ng/mL)	6.5 ±6.4 (0.14–30.1)
(−)-9-hydroxyrisperidone (ng/mL)	8.4 ±7.6 (0.5–44.0)
(+)-9-hydroxyrisperidone (ng/mL)	3.84 ±2.97 (0.4–12.6)
CYP2D6	n = 28
Phenotype	15 extensive metabolizer
	6 intermediate metabolizer
	7 poor metabolizer
Genotype	5(1/1); 8(1/2A); 2(1/2); 2(1/41); 1(1/4); 1(1/5); 1(1/6); 1(1/9); 1(4/4DUP); 5(4/4); 1(4/5)

SD = standard deviation; ng = nanograms; mL = millilitres; mg = milligrams; kg = kilograms; CYP2D6 = cytochrome P450 2D6; DUP = duplication.